Investor Centre

Pharmaxis CEO Mr Gary Phillips presented at the Proactive CEO Investor Session on Tuesday 10 November 2020. Mr Phillips discussed the significance of last week’s US FDA approval of Bronchitol for Pharmaxis and the Company’s focus on its new drug for the rare bone cancer myelofibrosis that will commence a phase 1c/2 clinical trial next quarter.

You may view a recording of the Session here. Mr Phillips' presentation starts at 43 minutes, 20 seconds.